Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date March 31, 2019 · Filed April 02, 2019
Section 16 reporting ended · disclosed 2019-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 5,936 |
Reported balance
After 2019-03-31 transaction · row 1
1 source rowRow 1 · 2019-03-31 · Disposition to issuer · Disposed 38,983 · Balance 5,936 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 760 |
Reported balance
Holding disclosure · report date 2019-03-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 760 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 1, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2019 Filed Apr 2, 2019 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Disposition to issuerCommon shares without par value | 38,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004522 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,936 Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $77.84 | $46,701.60 |
DisclosureSEC source: 0001179110-19-003619 · edgar.xml · nonDerivative · entry 5 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,919 Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $77.83 | $7,783.40 |
DisclosureSEC source: 0001179110-19-003619 · edgar.xml · nonDerivative · entry 4 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,519 Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $77.83 | $7,783.30 |
DisclosureSEC source: 0001179110-19-003619 · edgar.xml · nonDerivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,619 Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,300 | $77.83 | $334,673.30 |
DisclosureSEC source: 0001179110-19-003619 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,719 Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $77.83 | $31,132.04 |
DisclosureSEC source: 0001179110-19-003619 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,019 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,224 | $78.00 | $95,472.00 |
DisclosureSEC source: 0001179110-19-003110 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,419 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,678 | $77.23 | $361,281.94 |
DisclosureSEC source: 0001179110-19-003110 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,643 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 90,642 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002636 · edgar.xml · derivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,642 Underlying: Common shares · 90,642 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,214 on February 22, 2020, 30,214 on February 22, 2021, and 30,214 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002636 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,321 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $73.36 | $7,335.50 |
DisclosureSEC source: 0001179110-18-011959 · edgar.xml · nonDerivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,029 Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $73.35 | $7,335.01 |
DisclosureSEC source: 0001179110-18-011959 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,129 Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,532 | $73.35 | $112,373.73 |
DisclosureSEC source: 0001179110-18-011959 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,229 Read SEC document |
| July 30, 2018 Filed Jul 31, 2018 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 615 | $65.16 | $40,073.40 |
DisclosureSEC source: 0001179110-18-010031 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,761 Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 259 | $63.20 | $16,368.80 |
DisclosureSEC source: 0001179110-18-009885 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,376 Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 505 | $62.44 | $31,532.20 |
DisclosureSEC source: 0001179110-18-009647 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,635 Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $58.57 | $58,565.00 |
DisclosureSEC source: 0001179110-18-006429 · edgar.xml · nonDerivative · entry 4 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,140 Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 450 | $58.56 | $26,352.45 |
DisclosureSEC source: 0001179110-18-006429 · edgar.xml · nonDerivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,140 Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $58.56 | $23,424.04 |
DisclosureSEC source: 0001179110-18-006429 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,590 Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $58.56 | $17,568.00 |
DisclosureSEC source: 0001179110-18-006429 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,990 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $60.26 | $18,078.30 |
DisclosureSEC source: 0001179110-18-003787 · edgar.xml · nonDerivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,290 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $60.27 | $12,053.00 |
DisclosureSEC source: 0001179110-18-003787 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,590 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,600 | $60.27 | $96,427.20 |
DisclosureSEC source: 0001179110-18-003787 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,790 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,053 | $58.93 | $62,055.92 |
DisclosureSEC source: 0001179110-18-003300 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,390 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,056 | $60.55 | $124,490.80 |
DisclosureSEC source: 0001179110-18-003300 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,443 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 134,623 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002530 · edgar.xml · derivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,623 Underlying: Common shares · 134,623 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,875 on 02/16/2019, 44,874 on 02/16/2020, and 44,874 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002530 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,499 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $56.13 | $33,675.00 |
DisclosureSEC source: 0001179110-17-014780 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,018 Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,588 | $56.12 | $89,120.15 |
DisclosureSEC source: 0001179110-17-014780 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,618 Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $49.16 | $49,161.00 |
DisclosureSEC source: 0001179110-17-011052 · edgar.xml · nonDerivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,206 Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $49.16 | $29,496.00 |
DisclosureSEC source: 0001179110-17-011052 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,206 Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $49.17 | $19,666.00 |
DisclosureSEC source: 0001179110-17-011052 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,806 Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 22:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 35,730 | $0.00 Strike: $48.34 | $0.00 |
DisclosureSEC source: 0001179110-17-010338 · edgar.xml · derivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,730 Underlying: Common shares · 35,730 shares Expires 2027-07-09 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,910 on 7/10/2018, 11,910 on 7/10/2019, and 11,910 on 7/10/2020. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 22:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 5,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010338 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,206 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.